浅静脉功能不全治疗后通用与疾病特异性生活质量改善
该回顾性队列纳入2019至2024年连续545例浅静脉功能不全患者,采用射频热消融(RFA)后超声引导泡沫硬化剂(UGFS)治疗。治疗后HASTI与SF-6D各项评分均改善,VCSS由6.0±2.9降至3.9±2.6(P<.001)。
要点
- RFA后UGFS可同时改善疾病特异性(HASTI)与通用(SF-6D)生活质量。
- VCSS从6.0±2.9显著降至3.9±2.6(P<.001)。
- 既往妊娠是女性患者最突出的危险因素(66%)。
核心结论
- 对浅静脉功能不全患者行RFA后UGFS,可显著改善疾病特异性与通用生活质量指标,并降低VCSS。
研究设计与样本
- 回顾性病历复习,纳入2019至2024年连续545例接受RFA后UGFS治疗的浅静脉功能不全患者。
- 队列中女性395例(73%)、男性150例(28%),中位年龄62岁(均值60±14岁),中位BMI 27 kg/m2(均值28±7 kg/m2)。
主要发现
- HASTI与SF-6D所有测量指标均显示症状评分改善。
- VCSS由6.0±2.9降至3.9±2.6(P<.001)。
- 治疗前症状平均持续超过1年,最常见症状为疼痛、沉重/疲乏与抽筋。
- 既往妊娠见于66%的女性患者,为最突出危险因素。
临床怎么用
- 对浅静脉功能不全患者,除技术成功外应关注患者报告结局,RFA后UGFS可作为改善症状与生活质量的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Most of the publications on the treatment of superficial venous insufficiency (SVI) have focused on technical and anatomic success. There are relatively few studies assessing patient-reported outcomes (PROs) after SVI treatment. However, patients and payers are increasingly interested in such outcomes in addition to technical success. We examined PROs after treatment with endovenous radiofrequency thermal ablation (RFA) and ultrasound-guided foam sclerotherapy (UGFS) for patients with SVI. METHODS: A retrospective chart review was performed on 545 consecutive patients with SVI treated between 2019 and 2024. Data on patient demographics, risk factors, Clinical-Etiology-Anatomy-Pathophysiology (CEAP) classification, Venous Clinical Severity Score (VCSS), and PROs were collected. The cohort was 395 female (73%) and 150 male (28%), with a median age of 62 years (mean 60 ± 14 years) and a median body mass index of 27 kg/m2 (mean 28 ± 7 kg/m2). Most patients were White (n = 459, 84%), with 19 (4%) Black or African American, 7 (1%) Asian, and 39 (7%) other race; 21 (4%) declined to disclose. Prior venous disease was present in 382 patients (70%), whereas 163 (30%) had no history of venous disease. Patients completed two PROs, HASTI (Heaviness, Achiness, Swelling, Throbbing, Itching) and SF-6D (Short Form-6 Dimensions), before and after receiving treatment with RFA followed by UGFS. Data were analyzed using descriptive statistics and paired t tests to compare pre- and post-treatment outcomes. RESULTS: Most patients were women (72%), with an average age of 60 ± 14 years and an average body mass index of 28 ± 7. The average duration of symptoms before treatment was greater than 1 year, and the most common presenting symptoms included aches/pains, heaviness/tiredness, and cramping. Prior pregnancy was the most prominent risk factor for SVI, observed in 66% of female patients. All measures of HASTI and SF-6D showed improvements in symptom scores. VCSS also improved significantly, from 6.0 ± 2.9 to 3.9 ± 2.6 (P < .001). CONCLUSIONS: Treatment of SVI patients with RFA followed by UGFS significantly improves both disease-specific (HASTI) and general (SF-6D) quality-of-life measures in addition to a decrease in VCSS.
引用
- Cappellano K, Calzon M, Weldon S, et al. General and disease-specific quality-of-life improvement following superficial venous insufficiency treatment. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 41135796. doi:10.1016/j.jvsv.2025.102347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。